Biotech Values

[DewDiligence]

…I am not sure if Teva would have an alternative plan of action.

Their plan of action, such as it is, is to promote thrice-weekly Copaxone as an alternative to regular Copaxone (if the thrice-weekly product has been approved). However, as previously noted on this board, the thrice-weekly product has no medical advantage relative to ordinary Copaxone.